1
|
Li L, Zhang H, Wang L, Xie C, Yu H, Zhong Y. Optimization of supraclavicular lymph node clinical target volume delineation in high-risk breast cancer: a single center experience and recommendation. BMC Cancer 2023; 23:1168. [PMID: 38031013 PMCID: PMC10688076 DOI: 10.1186/s12885-023-11596-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2023] [Accepted: 11/01/2023] [Indexed: 12/01/2023] Open
Abstract
BACKGROUND Prophylactic irradiation of supraclavicular lymph node drainage areas can improve the regional control rate of lymph node-positive or lymph node-negative disease but a locally-advanced stage breast cancer, and it can reduce breast cancer-related mortality. However, many controversies exist in the clinical target volume delineation of supraclavicular lymph node drainage in patients with breast cancer. METHODS We retrospectively analyzed 42 patients with breast cancer and supraclavicular lymph node metastasis at our hospital between January 2017 and December 2021. Among these cases, 32 were locally advanced and 10 were stage IV at initial treatment. A patient with breast cancer who did not undergo dissection of the supraclavicular and infraclavicular lymph nodes at our hospital was selected as a standard patient. A contrast-enhanced computed tomography (CT) scan for positioning was used as a template image, and blood vessels, muscles, and bony landmarks were used as references for positioning. The metastatic supraclavicular lymph nodes were identified in all enrolled patients and projected into the template CT images. RESULTS The metastastic pattern of supraclavicular lymph node in breast cancer was proposed: distribution along the posterolateral border of the internal jugular vein (medial supraclavicular group) and along the transverse jugular vein (lateral supraclavicular group). We theorized that the lateral and posterior borders of the clinical target volume in the supraclavicular region should include the lymph nodes in the posterior triangle of the neck (level V) in high-risk individuals. If the metastatic axillary lymph node is extensive, then the superior border of the supraclavicular region should be moved upward appropriately. CONCLUSIONS This study analyzed patients with breast cancer and supraclavicular lymph node metastasis at initial treatment, explored the metastastic pattern of supraclavicular lymph node, and applied anatomical knowledge to further optimize the target volume delineation of supraclavicular lymph node drainage area in high-risk breast cancer.
Collapse
Affiliation(s)
- Li Li
- Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, #169, Donghu Road, Wuchang District, Wuhan, 430071, Hubei, China
- Hubei Cancer Clinical Study Center, #169, Donghu Road, Wuchang District, Wuhan, Hubei, 430071, China
- Hubei Key Laboratory of Tumor Biological Behaviors, #169, Donghu Road, Wuchang District, Wuhan, Hubei, 430071, China
| | - Hongyan Zhang
- Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, #169, Donghu Road, Wuchang District, Wuhan, 430071, Hubei, China
- Hubei Cancer Clinical Study Center, #169, Donghu Road, Wuchang District, Wuhan, Hubei, 430071, China
- Hubei Key Laboratory of Tumor Biological Behaviors, #169, Donghu Road, Wuchang District, Wuhan, Hubei, 430071, China
| | - Linwei Wang
- Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, #169, Donghu Road, Wuchang District, Wuhan, 430071, Hubei, China
- Hubei Cancer Clinical Study Center, #169, Donghu Road, Wuchang District, Wuhan, Hubei, 430071, China
- Hubei Key Laboratory of Tumor Biological Behaviors, #169, Donghu Road, Wuchang District, Wuhan, Hubei, 430071, China
| | - Conghua Xie
- Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, #169, Donghu Road, Wuchang District, Wuhan, 430071, Hubei, China
- Hubei Cancer Clinical Study Center, #169, Donghu Road, Wuchang District, Wuhan, Hubei, 430071, China
- Hubei Key Laboratory of Tumor Biological Behaviors, #169, Donghu Road, Wuchang District, Wuhan, Hubei, 430071, China
| | - Haijun Yu
- Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, #169, Donghu Road, Wuchang District, Wuhan, 430071, Hubei, China.
- Hubei Cancer Clinical Study Center, #169, Donghu Road, Wuchang District, Wuhan, Hubei, 430071, China.
- Hubei Key Laboratory of Tumor Biological Behaviors, #169, Donghu Road, Wuchang District, Wuhan, Hubei, 430071, China.
| | - Yahua Zhong
- Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, #169, Donghu Road, Wuchang District, Wuhan, 430071, Hubei, China.
- Hubei Cancer Clinical Study Center, #169, Donghu Road, Wuchang District, Wuhan, Hubei, 430071, China.
- Hubei Key Laboratory of Tumor Biological Behaviors, #169, Donghu Road, Wuchang District, Wuhan, Hubei, 430071, China.
| |
Collapse
|
2
|
Welgemoed C, Coughlan S, McNaught P, Gujral D, Riddle P. A dosimetric study to improve the quality of nodal radiotherapy in breast cancer. BJR Open 2021; 2:20210013. [PMID: 34381941 PMCID: PMC8320135 DOI: 10.1259/bjro.20210013] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2021] [Accepted: 03/07/2021] [Indexed: 11/06/2022] Open
Abstract
Objectives: Field-based planning for regional nodal breast radiotherapy (RT) used to be
standard practice. This study evaluated a field-based posterior axillary
boost (PAB) and two forward-planned intensity-modulated RT (IMRT)
techniques, aiming to replace the first. Methods: Supraclavicular and axillary nodes, humeral head, brachial plexus, thyroid,
and oesophagus were retrospectively delineated on 12 CT scans. Three plans,
prescribed to 40.05 Gy, were produced for each patient. Breast plans
consisted of field-in-field IMRT tangential fields in all three techniques.
Nodal plans consisted of a field-based PAB (anterior and posterior boost
beam), and 2 forward-planned techniques: simple IMRT 1 (anterior and
posterior beam with limited segments), and a more advanced IMRT 2 technique
(anterior and fully modulated posterior beam). Results: The nodal V90% was similar between IMRT 1: mean 99.5% (SD 1.0) and
IMRT 2: 99.4% (SD 0.5). Both demonstrated significantly improved results
(p = 0.0001 and 0.005, respectively) compared to
the field-based PAB technique. IMRT 2 lung V12Gy and humeral head
V10Gy were significantly lower (p = 0.002,
0.0001, respectively) than the field-based PAB technique. IMRT 1 exhibited
significantly lower brachial plexus Dmax and humeral head
V5, 10, and 15Gy doses
(p = 0.007, 0.013, 0.007 and 0.007, respectively)
compared to the field-based PAB technique. The oesophagus and thyroid dose
difference between methods was insignificant. Conclusions: Both IMRT techniques achieved the dose coverage requirements and reduced
normal tissue exposure, decreasing the risk of radiation side effects.
Despite the increased cost of IMRT, compared to non-IMRT techniques
1, both IMRT techniques are suitable for supraclavicular and
axillary nodal RT. Advances in knowledge: Forward-planned IMRT already resulted in significant dose reduction to organs
at risk and improved planning target volume coverage.1 This new, simplified
forward-planned IMRT one technique has not been published in this context
and is easy to implement in routine clinical practice.
Collapse
Affiliation(s)
| | - Simon Coughlan
- Radiotherapy Department, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK
| | - Patti McNaught
- Radiotherapy Department, Imperial College Healthcare NHS Trust, London, UK
| | | | - Pippa Riddle
- Radiotherapy Department, Imperial College Healthcare NHS Trust, London, UK
| |
Collapse
|
3
|
Novikov SN, Krzhivitskii PI, Melnik YS, Valitova AA, Bryantseva ZV, Akulova IA, Kanaev SV. Atlas of sentinel lymph nodes in early breast cancer using single-photon emission computed tomography: implication for lymphatic contouring. Radiat Oncol J 2021; 39:8-14. [PMID: 33794569 PMCID: PMC8024181 DOI: 10.3857/roj.2020.00871] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2020] [Accepted: 02/03/2021] [Indexed: 11/03/2022] Open
Abstract
PURPOSE to determine the localization of sentinel lymph nodes (SLNs) in a large cohort of patients with breast cancer and validate the European Society for Therapeutic Radiology and Oncology (ESTRO), Radiation Therapy Oncology Group (RTOG), and Radiotherapy Comparative Effectiveness (RADCOMP) guidelines on regional lymph node clinical target volume (CTV-LN) delineation. MATERIALS AND METHODS A total of 254 women with cT1-3N0-1M0 breast cancer underwent single-photon emission computed tomography (SPECT-CT) visualization of SLNs after intra- and peritumoral injection of 99mTc-radiocolloids. All SPECT-CT images were fused with reference simulation computed tomography. A 3D atlas of SLNs was created and used for evaluation of CTV-LN defined by contouring guidelines. RESULTS SPECT-CT visualized 532 SLNs that were localized in axillary level I in 67.5%, level II in 15.4%, level III in 7.3%, internal mammary in 8.5%, and supraclavicular in 1.3% cases. The majority of level II-IV and internal mammary SLNs were inside the recommended CTV-LN. Axillary level I SLNs were covered by ESTRO and RTOG contours in 85% and 85% cases, respectively. "Out of contours" SLNs were mostly detected in lateral subgroup of level I LN (18.5%), while 98%-99% of anterior pectoral and central axillary SLNs were covered by CTV-LN. Internal mammary SLNs were visualized in 33 cases and were outside ESTRO and RTOG contours in 3 and 6 observations, respectively. CONCLUSION SPECT-CT atlas of SLNs demonstrated that in most cases ESTRO and RTOG guidelines correctly represented CTV-LNs with the exception of lateral subgroup of SLNs.
Collapse
Affiliation(s)
- Sergey Nikolaevich Novikov
- Department of Radiation Oncology & Nuclear Medicine, N.N. Petrov National Medical Research Center of Oncology, St. Petersburg, Russia
| | - Pavel Ivanovich Krzhivitskii
- Department of Radiation Oncology & Nuclear Medicine, N.N. Petrov National Medical Research Center of Oncology, St. Petersburg, Russia
| | - Yulia Sergeevna Melnik
- Department of Radiation Oncology & Nuclear Medicine, N.N. Petrov National Medical Research Center of Oncology, St. Petersburg, Russia
| | - Alina Albertovna Valitova
- Department of Radiation Oncology & Nuclear Medicine, N.N. Petrov National Medical Research Center of Oncology, St. Petersburg, Russia
| | - Zhanna Viktorovna Bryantseva
- Department of Radiation Oncology & Nuclear Medicine, N.N. Petrov National Medical Research Center of Oncology, St. Petersburg, Russia
| | - Irina Alexandrovna Akulova
- Department of Radiation Oncology & Nuclear Medicine, N.N. Petrov National Medical Research Center of Oncology, St. Petersburg, Russia
| | - Sergey Vasilevich Kanaev
- Department of Radiation Oncology & Nuclear Medicine, N.N. Petrov National Medical Research Center of Oncology, St. Petersburg, Russia
| |
Collapse
|
4
|
Kaidar-Person O, Offersen BV, Boersma LJ, de Ruysscher D, Tramm T, Kühn T, Gentilini O, Mátrai Z, Poortmans P. A multidisciplinary view of mastectomy and breast reconstruction: Understanding the challenges. Breast 2021; 56:42-52. [PMID: 33610903 PMCID: PMC7905468 DOI: 10.1016/j.breast.2021.02.004] [Citation(s) in RCA: 24] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2020] [Revised: 01/25/2021] [Accepted: 02/05/2021] [Indexed: 12/18/2022] Open
Abstract
The current review paper was written in collaboration with breast cancer surgeons from the European Breast Cancer Research Association of Surgical Trialists (EUBREAST), a breast pathologist from the Danish Breast Cancer Group (DBCG), and representatives from the European SocieTy for Radiotherapy & Oncology (ESTRO) breast cancer course. Herein we summarize the different mastectomies and reconstruction procedures and define high-risk anatomical areas for breast cancer recurrences, to further specify the challenges in the surgical procedure, histopathological evaluation, and target volumes in case of postmastectomy irradiation, as recommended by the ESTRO guidelines according to the surgical procedure. The paper has original figures and illustrations for all disciplines for in-depth understanding of the differences between the procedures. Mastectomy techniques and reconstruction evolved to improve cosmetic outcomes. Different techniques maybe associated with different amount of residual breast tissue. More data is needed to estimate who are the patients at risk for residual disease or recurrence. Multidisciplinary work needed to individualise treatment for optimal oncological outcomes while maintaining the significant improvements in achieving better cosmesis for these patients.
Collapse
Affiliation(s)
- Orit Kaidar-Person
- Breast Cancer Radiation Therapy Unit, At Sheba Medical Center, Ramat Gan, Israel; Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel; GROW-School for Oncology and Developmental Biology (Maastro), Maastricht University, Maastricht, the Netherlands.
| | - Birgitte V Offersen
- Department of Experimental Clinical Oncology, Aarhus University Hospital, Denmark
| | - Liesbeth J Boersma
- GROW-School for Oncology and Developmental Biology (Maastro), Maastricht University, Maastricht, the Netherlands; Department of Radiation Oncology (Maastro), Maastricht University Medical Centre, Maastricht, the Netherlands
| | - Dirk de Ruysscher
- GROW-School for Oncology and Developmental Biology (Maastro), Maastricht University, Maastricht, the Netherlands; Department of Radiation Oncology (Maastro), Maastricht University Medical Centre, Maastricht, the Netherlands
| | - Trine Tramm
- Department of Pathology, Aarhus University Hospital, Denmark
| | - Thorsten Kühn
- Department of Gynaecology and Obstetrics, Interdisciplinary Breast Center, Klinikum Esslingen, Germany
| | - Oreste Gentilini
- Breast Surgery Unit, San Raffaele University Hospital, Milan, Italy
| | - Zoltán Mátrai
- Department of Breast and Sarcoma Surgery, National Institute of Oncology, Budapest, 1122, Budapest, Ráth György U 7, Hungary
| | - Philip Poortmans
- Iridium Kankernetwerk, 2610, Wilrijk-Antwerp, Belgium; University of Antwerp, Faculty of Medicine and Health Sciences, 2610, Wilrijk-Antwerp, Belgium
| |
Collapse
|
5
|
Rogé M, Thureau S, Dampierre J, Dubray B, Rivera S. [Prophylactic nodal radiotherapy for breast cancer]. Cancer Radiother 2019; 23:904-912. [PMID: 31594695 DOI: 10.1016/j.canrad.2019.08.006] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2019] [Revised: 08/16/2019] [Accepted: 08/20/2019] [Indexed: 11/24/2022]
Abstract
Adjuvant radiotherapy is a key treatment in early-stage breast cancer. The meta-analysis by the Early Breast Cancer Trialist's Collaborative Group (EBCTCG) has demonstrated a decreased risk of locoregional relapse and death after whole-breast radiotherapy. Prophylactic lymph nodes irradiation in breast cancer has also proven to be beneficial in several therapeutic trials. At a time when three-dimensional conformal radiotherapy has become the standard procedure and with the development of intensity-modulated radiation therapy, defining nodal volumes is essential and practices should be harmonized to assess and compare the efficiency and toxicity of radiotherapy. Furthermore, the indication of lymph nodes irradiation has to take into account the risk/benefit balance as expanding the irradiated volume can increase radio-induced toxicity. Selection of patients receiving this treatment is essential. The aim of this update is to define nodal volumes, to precise the indications of their irradiation and to present the expected benefits as well as the potential side effects.
Collapse
Affiliation(s)
- M Rogé
- Département d'oncologie radiothérapie, centre Henri-Becquerel, 1, rue d'Amiens,76000 Rouen, France.
| | - S Thureau
- Département d'oncologie radiothérapie, centre Henri-Becquerel, 1, rue d'Amiens,76000 Rouen, France
| | - J Dampierre
- Service de pneumologie oncologie thoracique et soins intensifs respiratoires, centre hospitalier universitaire de Rouen, 1, rue de Germont, 76000 Rouen, France
| | - B Dubray
- Département d'oncologie radiothérapie, centre Henri-Becquerel, 1, rue d'Amiens,76000 Rouen, France
| | - S Rivera
- Gustave-Roussy Cancer Campus, 114, rue Édouard-Vaillant, 94805 Villejuif, France; Université Paris-Sud, 114, rue Édouard-Vaillant, 94805 Villejuif, France
| |
Collapse
|
6
|
FDG/PET-CT–Based Lymph Node Atlas in Breast Cancer Patients. Int J Radiat Oncol Biol Phys 2019; 103:574-582. [DOI: 10.1016/j.ijrobp.2018.07.2025] [Citation(s) in RCA: 36] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2018] [Revised: 06/27/2018] [Accepted: 07/04/2018] [Indexed: 11/18/2022]
|
7
|
Gee HE, Moses L, Stuart K, Nahar N, Tiver K, Wang T, Ward R, Ahern V. Contouring consensus guidelines in breast cancer radiotherapy: Comparison and systematic review of patterns of failure. J Med Imaging Radiat Oncol 2018; 63:102-115. [PMID: 30267561 DOI: 10.1111/1754-9485.12804] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2018] [Accepted: 08/16/2018] [Indexed: 11/28/2022]
Abstract
Adequate coverage of sites harbouring potential microscopic disease is paramount, where the clinical decision has been made to include regional lymph node radiotherapy for patients with breast cancer. This must be achieved in balance with minimising dose to normal tissues. Several international consensus guidelines detailing clinical target volumes (CTVs) are available, but there is currently no agreement as to which is most appropriate for a given clinical situation. Contouring guidelines are beneficial for routine practice and essential for clinical trial quality assurance. The aims of this study were as follows: to provide a single point of comparison of four commonly used contouring guidelines, including one used in a current Trans-Tasman Radiation Oncology Group trial; and to undertake a systematic review of existing studies which map sites of breast cancer recurrence against contouring guidelines. Two international consensus guidelines (European Society for Radiotherapy and Oncology, and Radiation Therapy Oncology Group) were compared with two clinical trial guidelines (TROG 12.02 PET LABRADOR and the Proton/Photon trial NCT02603341 RADCOMP). Comprehensive literature search for patterns of failure studies was undertaken using Embase and Pubmed. We detail the small but significant differences between the breast consensus guidelines, particularly the supraclavicular (SCF) and internal mammary chain CTVs. Seven series were found mapping recurrence patterns. These results are discussed in the context of the contouring guidelines. Several studies found the SCF CTV is the area at greatest risk of geographical 'miss'. This review will facilitate further discussion about guideline selection and modification, particularly for future clinical trials in Australia and New Zealand.
Collapse
Affiliation(s)
- Harriet E Gee
- Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, New South Wales, Australia.,Sydney Medical School, C24 - Westmead Hospital, The University of Sydney, Sydney, New South Wales, Australia.,Westmead Breast Cancer Institute, Westmead Hospital, Sydney, New South Wales, Australia
| | - Lauren Moses
- Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, New South Wales, Australia
| | - Kirsty Stuart
- Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, New South Wales, Australia.,Sydney Medical School, C24 - Westmead Hospital, The University of Sydney, Sydney, New South Wales, Australia.,Westmead Breast Cancer Institute, Westmead Hospital, Sydney, New South Wales, Australia
| | - Najmun Nahar
- Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, New South Wales, Australia
| | - Ken Tiver
- Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, New South Wales, Australia.,Nepean Cancer Care Centre, Nepean Hospital, New South Wales, Australia
| | - Tim Wang
- Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, New South Wales, Australia.,Sydney Medical School, C24 - Westmead Hospital, The University of Sydney, Sydney, New South Wales, Australia.,Westmead Breast Cancer Institute, Westmead Hospital, Sydney, New South Wales, Australia
| | - Rachel Ward
- Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, New South Wales, Australia
| | - Verity Ahern
- Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, New South Wales, Australia.,Sydney Medical School, C24 - Westmead Hospital, The University of Sydney, Sydney, New South Wales, Australia.,Westmead Breast Cancer Institute, Westmead Hospital, Sydney, New South Wales, Australia
| |
Collapse
|
8
|
Mutter RW, Remmes NB, Kahila MMH, Hoeft KA, Pafundi DH, Zhang Y, Corbin KS, Park SS, Yan ES, Lemaine V, Boughey JC, Beltran CJ. Initial clinical experience of postmastectomy intensity modulated proton therapy in patients with breast expanders with metallic ports. Pract Radiat Oncol 2017; 7:e243-e252. [DOI: 10.1016/j.prro.2016.12.002] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2016] [Revised: 12/07/2016] [Accepted: 12/12/2016] [Indexed: 11/30/2022]
|
9
|
Chang JS, Byun HK, Kim YB. Reply to the Letter to the Editor by Vargo et al. Radiother Oncol 2017; 123:485. [PMID: 28554499 DOI: 10.1016/j.radonc.2017.05.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2017] [Accepted: 05/04/2017] [Indexed: 11/30/2022]
Affiliation(s)
- Jee Suk Chang
- Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea
| | - Hwa Kyung Byun
- Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea
| | - Yong Bae Kim
- Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.
| |
Collapse
|
10
|
Nielsen HM, Friis RB, Linnet S, Offersen BV. Loco-regional morbidity after breast conservation and axillary lymph node dissection for early breast cancer with or without regional nodes radiotherapy, perspectives in modern breast cancer treatment: the Skagen Trial 1 is active. Acta Oncol 2017; 56:713-718. [PMID: 28105873 DOI: 10.1080/0284186x.2016.1277261] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
BACKGROUND Axillary lymph node dissection (ALND) and adjuvant radiotherapy (RT) in early breast cancer are associated with a risk of morbidity, including lymphedema and impaired shoulder mobility. The aim of this study was to evaluate loco-regional morbidity after breast conserving surgery (BCS), ALND, taxane-based chemotherapy and whole breast irradiation (WBI) with or without regional nodes RT. MATERIAL AND METHODS Eligible patients had BCS and ALND from 2007 to 2012 followed by adjuvant taxane-based chemotherapy and if indicated, trastuzumab and endocrine treatment. The RT consisted of WBI and regional nodes RT in case of ≥ pN1 disease (group 1) and WBI only in case of pN0-1(mic) disease (group 2). The dose was 50 Gy in 25 fractions. The patients were invited to participate in a cross-sectional study evaluating morbidity. RESULTS Of the 347 eligible patients, 277 patients (79%) accepted the invitation. Of these, 185 patients (67%) belonged to group 1 and 92 patients (33%) to group 2. The median time from RT to evaluation of morbidity was 3.3 years (group 1) and 4.3 years (group 2). In group 1, 34 patients (18%) and in group 2, 15 patients (16%) had ≥2 cm enlargement in circumference of ipsilateral upper or lower arm (p = .67). The frequence of impairment of ipsilateral shoulder abduction to ≤120° was 3% in both groups and of shoulder flexion to ≤120° was 1% and 2% (group 1 versus 2). No difference in patient reported outcome measure (PROM) data regarding heaviness or enlargement of ipsilateral upper and lower arm or mobility and sensory disturbances. CONCLUSION The risk of lymphedema was low in patients after ALND and not related to use of regional nodes RT. Impairment of shoulder function was rare, and no differences in PROM were detected regarding use or not of regional nodes RT.
Collapse
Affiliation(s)
| | | | - Søren Linnet
- Department of Oncology, Herning Hospital, Herning, Denmark
| | | |
Collapse
|
11
|
Chang JS, Byun HK, Kim JW, Kim KH, Lee J, Cho Y, Lee IJ, Keum KC, Suh CO, Kim YB. Three-dimensional analysis of patterns of locoregional recurrence after treatment in breast cancer patients: Validation of the ESTRO consensus guideline on target volume. Radiother Oncol 2017; 122:24-29. [DOI: 10.1016/j.radonc.2016.10.016] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2016] [Revised: 10/04/2016] [Accepted: 10/17/2016] [Indexed: 10/20/2022]
|
12
|
Kaidar-Person O, Kostich M, Zagar TM, Jones E, Gupta G, Mavroidis P, Das SK, Marks LB. Helical tomotherapy for bilateral breast cancer: Clinical experience. Breast 2016; 28:79-83. [DOI: 10.1016/j.breast.2016.05.004] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2016] [Revised: 05/11/2016] [Accepted: 05/11/2016] [Indexed: 01/01/2023] Open
|
13
|
Offersen BV, Boersma LJ, Kirkove C, Hol S, Aznar MC, Sola AB, Kirova YM, Pignol JP, Remouchamps V, Verhoeven K, Weltens C, Arenas M, Gabrys D, Kopek N, Krause M, Lundstedt D, Marinko T, Montero A, Yarnold J, Poortmans P. ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer, version 1.1. Radiother Oncol 2016; 118:205-8. [DOI: 10.1016/j.radonc.2015.12.027] [Citation(s) in RCA: 108] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2015] [Accepted: 12/05/2015] [Indexed: 10/22/2022]
|
14
|
Rivera S, Louvel G, Rivin Del Campo E, Boros A, Oueslati H, Deutsch É. [Prophylactic axillary radiotherapy for breast cancer]. Cancer Radiother 2015; 19:253-60. [PMID: 26044178 DOI: 10.1016/j.canrad.2015.05.001] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2015] [Revised: 05/02/2015] [Accepted: 05/07/2015] [Indexed: 01/25/2023]
Abstract
Adjuvant radiotherapy, after breast conserving surgery or mastectomy for breast cancer, improves overall survival while decreasing the risk of recurrence. However, prophylactic postoperative radiotherapy of locoregional lymph nodes for breast cancer, particularly of the axillary region, is still controversial since the benefits and the risks due to axillary irradiation have not been well defined. To begin with, when performing conformal radiotherapy, volume definition is crucial for the analysis of the risk-benefit balance of any radiation treatment. Definition and contouring of the axillary lymph node region is discussed in this work, as per the recommendations of the European Society for Radiotherapy and Oncology (ESTRO). Axillary recurrences are rare, and the recent trend leads toward less aggressive surgery with regard to the axilla. In this literature review we present the data that lead us to avoid adjuvant axillary radiotherapy in pN0, pN0i+ and pN1mi patients even without axillary clearance and to perform it in some other situations. Finally, we propose an update about the potential toxicity of adjuvant axillary irradiation, which is essential for therapeutic decision-making based on current evidence, and to guide us in the evolution of our techniques and indications of axillary radiotherapy.
Collapse
Affiliation(s)
- S Rivera
- Département d'oncologie radiothérapie, institut Gustave-Roussy, 114, rue Édouard-Vaillant, 94800 Villejuif, France.
| | - G Louvel
- Département d'oncologie radiothérapie, institut Gustave-Roussy, 114, rue Édouard-Vaillant, 94800 Villejuif, France
| | - E Rivin Del Campo
- Département d'oncologie radiothérapie, institut Gustave-Roussy, 114, rue Édouard-Vaillant, 94800 Villejuif, France
| | - A Boros
- Département d'oncologie radiothérapie, institut Gustave-Roussy, 114, rue Édouard-Vaillant, 94800 Villejuif, France
| | - H Oueslati
- Département d'oncologie radiothérapie, institut Gustave-Roussy, 114, rue Édouard-Vaillant, 94800 Villejuif, France
| | - É Deutsch
- Département d'oncologie radiothérapie, institut Gustave-Roussy, 114, rue Édouard-Vaillant, 94800 Villejuif, France
| |
Collapse
|
15
|
Offersen BV, Boersma LJ, Kirkove C, Hol S, Aznar MC, Biete Sola A, Kirova YM, Pignol JP, Remouchamps V, Verhoeven K, Weltens C, Arenas M, Gabrys D, Kopek N, Krause M, Lundstedt D, Marinko T, Montero A, Yarnold J, Poortmans P. ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer. Radiother Oncol 2015; 114:3-10. [PMID: 25630428 DOI: 10.1016/j.radonc.2014.11.030] [Citation(s) in RCA: 450] [Impact Index Per Article: 45.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2014] [Revised: 11/15/2014] [Accepted: 11/15/2014] [Indexed: 12/25/2022]
Abstract
BACKGROUND AND PURPOSE Delineation of clinical target volumes (CTVs) is a weak link in radiation therapy (RT), and large inter-observer variation is seen in breast cancer patients. Several guidelines have been proposed, but most result in larger CTVs than based on conventional simulator-based RT. The aim was to develop a delineation guideline obtained by consensus between a broad European group of radiation oncologists. MATERIAL AND METHODS During ESTRO teaching courses on breast cancer, teachers sought consensus on delineation of CTV through dialogue based on cases. One teacher delineated CTV on CT scans of 2 patients, followed by discussion and adaptation of the delineation. The consensus established between teachers was sent to other teams working in the same field, both locally and on a national level, for their input. This was followed by developing a broad consensus based on discussions. RESULTS Borders of the CTV encompassing a 5mm margin around the large veins, running through the regional lymph node levels were agreed, and for the breast/thoracic wall other vessels were pointed out to guide delineation, with comments on margins for patients with advanced breast cancer. CONCLUSION The ESTRO consensus on CTV for elective RT of breast cancer, endorsed by a broad base of the radiation oncology community, is presented to improve consistency.
Collapse
Affiliation(s)
| | - Liesbeth J Boersma
- Department of Radiation Oncology, Maastricht University Medical Centre - GROW (MAASTRO), The Netherlands
| | - Carine Kirkove
- Department of Radiation Oncology, Catholic University of Louvain, Belgium
| | - Sandra Hol
- Department of Radiation Oncology, Institute Verbeeten, Tilburg, The Netherlands
| | | | - Albert Biete Sola
- Department of Radiation Oncology, Hospital Clinic i Provincial, Barcelona, Spain
| | - Youlia M Kirova
- Department of Radiation Oncology, Institut Curie, Paris, France
| | - Jean-Philippe Pignol
- Department of Radiation Oncology, Erasmus University Medical Center, Rotterdam, The Netherlands
| | - Vincent Remouchamps
- Department of Radiation Oncology, Clinique Sainte Elisabeth (AMPR), Namur, Belgium
| | - Karolien Verhoeven
- Department of Radiation Oncology, University Hospitals Leuven, KU Leuven, Belgium
| | - Caroline Weltens
- Department of Radiation Oncology, University Hospitals Leuven, KU Leuven, Belgium
| | - Meritxell Arenas
- Department of Radiation Oncology, Hospital Universitari Sant Joan, Reus, Spain
| | - Dorota Gabrys
- Department of Radiation Oncology, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Gliwice, Poland
| | - Neil Kopek
- Department of Oncology, Division of Radiation Oncology, McGill University, Montréal, Canada
| | - Mechthild Krause
- German Cancer Consortium (DKTK) Dresden and German Cancer Research Center (DKFZ) Heidelberg, Dept. of Radiation Oncology and OncoRay, University Hospital Carl Gustav Carus, Technische Universität Dresden and Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany
| | - Dan Lundstedt
- Department of Oncology, Sahlgrenska Universitetssjukhuset, Gothenborg, Sweden
| | - Tanja Marinko
- Department of Radiation Oncology, Institute of Oncology, Ljubljana, Slovenia
| | - Angel Montero
- Department of Radiation Oncology, Centro Integral Oncológico Clara Campal, Hospital Universitario Sanchinarro, Madrid, Spain
| | - John Yarnold
- Division of Radiotherapy and Imaging, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, UK
| | - Philip Poortmans
- Department of Radiation Oncology, Radboud university medical centre, The Netherlands
| |
Collapse
|